{
    "id": 25303,
    "fullName": "HSPA5 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "HSPA5 positive indicates the presence of the HSPA5 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3309,
        "geneSymbol": "HSPA5",
        "terms": [
            "HSPA5",
            "BIP",
            "GRP78",
            "HEL-S-89n",
            "MIF2"
        ]
    },
    "variant": "positive",
    "createDate": "09/01/2016",
    "updateDate": "01/21/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8209,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of dexamethasone, Revlimid (lenolidomide), and PAT-SM6 worked synergistically to inhibit growth of a Revlimid (lenolidomide)-resistant multiple myeloma cell lines with HSPA5 (GRP78) expression in culture (PMID: 27029491).",
            "molecularProfile": {
                "id": 26175,
                "profileName": "HSPA5 positive"
            },
            "therapy": {
                "id": 4660,
                "therapyName": "Dexamethasone + Lenalidomide + PAT-SM6",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6555,
                    "pubMedId": 27029491,
                    "title": "A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029491"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8202,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Revlimid (lenalidomide) and PAT-SM6 worked synergistically to inhibit growth of both drug-resistant and sensitive multiple myeloma cell lines with HSPA5 (GRP78) expression in culture (PMID: 27029491).",
            "molecularProfile": {
                "id": 26175,
                "profileName": "HSPA5 positive"
            },
            "therapy": {
                "id": 4658,
                "therapyName": "Lenalidomide + PAT-SM6",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6555,
                    "pubMedId": 27029491,
                    "title": "A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029491"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8144,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with Velcade (bortezomib), Revlimid (lenalidomide), and PAT-SM6 resulted in an initial response in a patient with refractory multiple myeloma expressing HSPA5 (GRP78), however, the patient progressed after 8 weeks (PMID: 27029491).",
            "molecularProfile": {
                "id": 26175,
                "profileName": "HSPA5 positive"
            },
            "therapy": {
                "id": 4642,
                "therapyName": "Bortezomib + Lenalidomide + PAT-SM6",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6555,
                    "pubMedId": 27029491,
                    "title": "A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029491"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8206,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PAT-SM6 and dexamethasone worked synergistically to inhibit growth of both drug-resistant and sensitive multiple myeloma cell lines with HSPA5 (GRP78) expression in culture (PMID: 27029491).",
            "molecularProfile": {
                "id": 26175,
                "profileName": "HSPA5 positive"
            },
            "therapy": {
                "id": 4659,
                "therapyName": "Dexamethasone + PAT-SM6",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6555,
                    "pubMedId": 27029491,
                    "title": "A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27029491"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26175,
            "profileName": "HSPA5 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}